Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer

Cell(2020)10.1016/j.cell.2020.05.017Source: DataRank Database

Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer is a research paper published in Cell (2020). On theSindex it has a DataRank of 5.5. It has been cited 749 times, with 100 citing works in its 1-hop citation network.

N/A

5.5DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access749 citations · 100 citing works in its network

Download PDF

Cite:

Linked data & code

geo gen nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02451423

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (29 grants)OA: bronzeTopics (40)IDs (PubMed, PMC)Annotations (3)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 18%Citation Network 82%

Base Score Contribution

0.993

From this paper's citation signal

Citation Network Contribution

4.5

From 100 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 100 citers.

Decade-long leukaemia remissions with persistence of CD4+ CAR T cells
Nature2022929 citations26 referencesContributes 0.263
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
Clinical Cancer Research202249 citations23 referencesContributes 0.170
Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma
Nature2021564 citations40 referencesContributes 0.158
Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma
Nature Medicine2021525 citations50 referencesContributes 0.125
Cuproptosis Induced by ROS Responsive Nanoparticles with Elesclomol and Copper Combined with αPD‐L1 for Enhanced Cancer Immunotherapy
Advanced Materials2023386 citations49 referencesContributes 0.122

Authors (20)

Serena S. Kwek ORCID,Siddharth S. Raju ORCID,Tony Li ORCID,Elizabeth McCarthy ORCID,Eric D. Chow ORCID

Live enrichment

PubMed:32497499 PMC:PMC7321885

National Institutes of Health

Grant: T32CA177555

National Institutes of Health

Grant: K08AI139375

NCI NIH HHS

Grant: R01 CA223484

NCI NIH HHS

Grant: U01 CA233100

NCI NIH HHS

Grant: U01 CA244452

NIGMS NIH HHS

Grant: T32 GM007618

NIAMS NIH HHS

Grant: P30 AR070155

NCI NIH HHS

Grant: R01 CA194511

NIGMS NIH HHS

Grant: T32 GM067547

National Institutes of Health

Grant: 1U01CA233100-01

Molecular and immune drivers of immunotherapy responsiveness in prostate cancer

National Institutes of Health

Grant: 3U01CA244452-01S2

Mechanisms of Exosome Driven Immunoregulation of Cancer Progression

National Institutes of Health

Grant: 5R01CA223484-02

Determinants of prostate cancer sensitivity to PD-1 blockade

National Institutes of Health

Grant: 5K08AI139375-04

Identification of circulating and tissue-specific autoimmune responses in checkpoint inhibitor-induced immune-related adverse events

National Institutes of Health

Grant: 5R01CA194511-04

Immunotherapy of human bladder cancer

National Institutes of Health

Grant: 5T32CA177555-03

Molecular Pathology of Cancer

Bavarian Nordic

Cancer Moonshot

University of California, San Francisco

Merck

Peter Michael Foundation

Prostate Cancer Foundation

Parker Institute for Cancer Immunotherapy

Conquer Cancer Foundation

Bladder Cancer Advocacy Network

AbbVie

American Society of Clinical Oncology

National Cancer Institute

Bristol-Myers Squibb

Janssen Pharmaceuticals

bronzeLicense: CC BY NC ND

publisherhttp://www.cell.com/article/S0092867420306127/pdf

publisherhttps://api.elsevier.com/content/article/PII:S0092867420306127?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0092867420306127?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7321885

Europe_PMChttps://europepmc.org/articles/PMC7321885

Fields of Study

03 medical and health sciences0302 clinical medicine

MeSH Terms

CD4-Positive T-LymphocytesCD8-Positive T-LymphocytesLymphocytes, Tumor-InfiltratingHumansReceptors, Antigen, T-CellImmunotherapyGenes, MHC Class IIGene Expression Regulation, NeoplasticT-Lymphocytes, RegulatoryUrinary Bladder NeoplasmsBiomarkers, PharmacologicalSingle-Cell AnalysisProgrammed Cell Death 1 ReceptorB7-H1 AntigenImmune Checkpoint Inhibitors

Keywords

Bladder cancerSingle-cell SequencingPd-1 BlockadeCheckpoint InhibitionAnti-pd-l1Predictive Gene SignatureCytotoxic Cd4(+) T cellsCD4-Positive T-LymphocytesGenes, MHC Class IIProgrammed Cell Death 1 ReceptorReceptors, Antigen, T-CellCD8-Positive T-LymphocytesT-Lymphocytes, RegulatoryArticleB7-H1 AntigenBiomarkers, PharmacologicalGene Expression Regulation, NeoplasticLymphocytes, Tumor-InfiltratingUrinary Bladder NeoplasmsHumansImmunotherapySingle-Cell AnalysisImmune Checkpoint Inhibitors

Sustainable Development Goals

SDG 3: 3. Good health